Welcome to LookChem.com Sign In|Join Free

CAS

  • or

6027-13-0 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 6027-13-0 Structure
  • Basic information

    1. Product Name: L-HOMOCYSTEINE
    2. Synonyms: BUTANOIC ACID, 2-AMINO-4-MERCAPTO-, (S)-;BUTYRIC ACID, 2-AMINO-4-MERCAPTO-, L-;L-HOMOCYSTEINE;(S)-HOMOCYSTEINE;(S)-2-AMINO-4-MERCAPTOBUTANOIC ACID;H-Hcys-OH;(S)-2-Amino-4-(methylmercapto)butanoic acid;Butyric acid, 2-amino-4-(methylthio)-, L-
    3. CAS NO:6027-13-0
    4. Molecular Formula: C4H9NO2S
    5. Molecular Weight: 135.18
    6. EINECS: 227-891-0
    7. Product Categories: Amino Acids
    8. Mol File: 6027-13-0.mol
    9. Article Data: 34
  • Chemical Properties

    1. Melting Point: 232°C
    2. Boiling Point: 299.691 °C at 760 mmHg
    3. Flash Point: 135.048 °C
    4. Appearance: /solid
    5. Density: 1.149 (estimate)
    6. Refractive Index: 1.5480 (estimate)
    7. Storage Temp.: ?20°C
    8. Solubility: Aqueous Acid (Sparingly, Heated, Sonicated), Water (Slightly, Heated)
    9. PKA: 2.24±0.10(Predicted)
    10. Stability: Air Sensitive, Hygroscopic
    11. CAS DataBase Reference: L-HOMOCYSTEINE(CAS DataBase Reference)
    12. NIST Chemistry Reference: L-HOMOCYSTEINE(6027-13-0)
    13. EPA Substance Registry System: L-HOMOCYSTEINE(6027-13-0)
  • Safety Data

    1. Hazard Codes: Xn
    2. Statements: 22
    3. Safety Statements: 22-24/25
    4. WGK Germany: 3
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 6027-13-0(Hazardous Substances Data)

6027-13-0 Usage

Description

L-Homocysteine, with the L configuration, is an essential non-protein amino acid that plays a crucial role in various biological processes. It is the hydrolysis product of adenosine, a purine nucleoside, and is involved in the metabolic conversion back to L-Methionine via tetrahydrofolate.

Uses

1. Used in Diagnostic Applications:
L-Homocysteine is used as a diagnostic marker for homocystinuria, a genetic disorder characterized by elevated levels of homocysteine in the blood and urine. This application helps in the early detection and management of the condition.
2. Used in Cell Culture Media:
L-Homocysteine has been utilized as a supplement in cell culture media to support the growth and maintenance of various cell types. Its presence in the media provides essential nutrients and promotes cell viability.
3. Used in Metabolic Studies:
As a key player in the metabolic conversion of L-Methionine, L-Homocysteine is used in research and studies focusing on the understanding of metabolic pathways and the role of tetrahydrofolate in cellular processes.

Biochem/physiol Actions

Elevated homocysteine levels in plasma and tissue are associated with brain atrophy in Alzheimer′s disease as well as in healthy eldery subjects. Increased homocysteine is due to deficiencies in vitamin B status, specifically folate, B6 and B12 vitamins, which act as cofactors for enzymes involved in homocysteine metabolism.

Purification Methods

Crystallise L-homocysteine from aqueous EtOH. All operations should be carried out under N2 as the thiol readily oxidizes in air. The acid (3g) is dissolved in freshly boiled H2O (

Check Digit Verification of cas no

The CAS Registry Mumber 6027-13-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,0,2 and 7 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 6027-13:
(6*6)+(5*0)+(4*2)+(3*7)+(2*1)+(1*3)=70
70 % 10 = 0
So 6027-13-0 is a valid CAS Registry Number.
InChI:InChI=1/C4H9NO2S/c5-3(1-2-8)4(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m0/s1

6027-13-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name L-homocysteine

1.2 Other means of identification

Product number -
Other names L-2-Amino-4-Mercapto-butyric acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:6027-13-0 SDS

6027-13-0Synthetic route

L-homocysteine thiolactone hydrochloride
31828-68-9

L-homocysteine thiolactone hydrochloride

L-homocysteine
6027-13-0

L-homocysteine

Conditions
ConditionsYield
With sodium hydroxide at 37℃; for 0.0833333h;96%
With water Alkaline conditions;
Alkaline conditions;
L-methionine
63-68-3

L-methionine

L-homocysteine
6027-13-0

L-homocysteine

Conditions
ConditionsYield
With ammonia; sodium at -60℃; for 0.5h;93%
With ammonia; sodium
With ammonia; sodium; ammonium chloride at -80℃; for 0.666667h;
Stage #1: L-methionine With ammonia; sodium at -78℃; Inert atmosphere;
Stage #2: With ammonium acetate In ammonia Inert atmosphere;
With sodium In ethanol at 0℃; for 8h; Solvent; Reagent/catalyst; Temperature;
(S)-1,3-thiazane-4-carboxylic acid
147331-83-7

(S)-1,3-thiazane-4-carboxylic acid

L-homocysteine
6027-13-0

L-homocysteine

Conditions
ConditionsYield
With hydroxylamine hydrochloride; triethylamine In ethanol for 1h; Heating;91.9%
Conditions
ConditionsYield
With ammonia; sodium Reduction;90%
With ammonia; sodium
With sodium In ammonia at -50℃;
With diothiothreitol at 30℃; for 5h;
With DL-dithiothreitol for 3.5h; pH=12;
(4S)-1,3-thiazane-2,4-dicarboxylic acid hydrochloride

(4S)-1,3-thiazane-2,4-dicarboxylic acid hydrochloride

L-homocysteine
6027-13-0

L-homocysteine

Conditions
ConditionsYield
With hydroxylamine hydrochloride; triethylamine In ethanol at 78℃; for 1.41667h; pH=6 - 7;81.5%
(2S,4S)-1,3-thiazine-2,4-dicarboxylic acid hydrochloride

(2S,4S)-1,3-thiazine-2,4-dicarboxylic acid hydrochloride

L-homocysteine
6027-13-0

L-homocysteine

Conditions
ConditionsYield
With hydroxylamine hydrochloride; triethylamine In ethanol for 1h; Ring cleavage; elimination; Heating;78.4%
(2S)-2-amino-4-(tritylsulfanyl)butanoic acid
69955-57-3

(2S)-2-amino-4-(tritylsulfanyl)butanoic acid

L-homocysteine
6027-13-0

L-homocysteine

Conditions
ConditionsYield
With ammonia; sodium at -33℃; for 1h; Reduction;52%
S-benzyl-L-homocysteine
7689-60-3

S-benzyl-L-homocysteine

L-homocysteine
6027-13-0

L-homocysteine

Conditions
ConditionsYield
With ammonia; sodium
GLUTATHIONE
70-18-8

GLUTATHIONE

A

L-homocysteine
6027-13-0

L-homocysteine

B

(S)-2-Amino-4-[(R)-2-((S)-3-amino-3-carboxy-propyldisulfanyl)-1-(carboxymethyl-carbamoyl)-ethylcarbamoyl]-butyric acid
75027-08-6

(S)-2-Amino-4-[(R)-2-((S)-3-amino-3-carboxy-propyldisulfanyl)-1-(carboxymethyl-carbamoyl)-ethylcarbamoyl]-butyric acid

Conditions
ConditionsYield
With sodium chloride In water-d2 at 25℃; Equilibrium constant; various pD values;
GLUTATHIONE
70-18-8

GLUTATHIONE

(S)-2-Amino-4-[(R)-2-((S)-3-amino-3-carboxy-propyldisulfanyl)-1-(carboxymethyl-carbamoyl)-ethylcarbamoyl]-butyric acid
75027-08-6

(S)-2-Amino-4-[(R)-2-((S)-3-amino-3-carboxy-propyldisulfanyl)-1-(carboxymethyl-carbamoyl)-ethylcarbamoyl]-butyric acid

A

Oxidized glutathione
27025-41-8

Oxidized glutathione

B

L-homocysteine
6027-13-0

L-homocysteine

Conditions
ConditionsYield
With sodium chloride In water-d2 at 25℃; Equilibrium constant; various pD values;
L-cystathionine
56-88-2

L-cystathionine

pyridoxal
66-72-8

pyridoxal

copper (2+)

copper (2+)

A

L-homocysteine
6027-13-0

L-homocysteine

B

2-oxo-propionic acid
127-17-3

2-oxo-propionic acid

C

pyridoxamine
85-87-0

pyridoxamine

Conditions
ConditionsYield
at 37℃; sowie in Gegenwart von weiteren Metallionen jeweils in gepufferter wss. Loesung;
(2S,4'S)-4-(benzylthio)-2-(2'-oxo-4'-phenyloxazolidin-3'-yl)butanoic acid

(2S,4'S)-4-(benzylthio)-2-(2'-oxo-4'-phenyloxazolidin-3'-yl)butanoic acid

B

L-homocysteine
6027-13-0

L-homocysteine

Conditions
ConditionsYield
With ammonia; lithium In tetrahydrofuran; tert-butyl alcohol at -70℃; for 0.0833333h; Elimination; Birch-Evans method;
S-ribosyl-L-homocysteine (β-form)

S-ribosyl-L-homocysteine (β-form)

A

L-homocysteine
6027-13-0

L-homocysteine

B

(4S)-4,5-dihydroxy-2,3-pentanedione
710324-30-4

(4S)-4,5-dihydroxy-2,3-pentanedione

Conditions
ConditionsYield
With MES buffer; E. coli S-ribosylhomocysteinase; S-<(3-carboxy-4-nitrophenyl)thio>-2-aminoethanethiol pH=6; Enzyme kinetics; Kinetics; Further Variations:; Reagents; pH-values; Enzymatic reaction;
L-homocysteine
6027-13-0

L-homocysteine

DL-methionine
59-51-8

DL-methionine

A

DL-homocystine sulfate

DL-homocystine sulfate

B

L-homocysteine
6027-13-0

L-homocysteine

Conditions
ConditionsYield
With sulfuric acid; hydrogen bromide In nitrogen
L-cystathionine
56-88-2

L-cystathionine

A

L-homocysteine
6027-13-0

L-homocysteine

B

2-oxo-propionic acid
127-17-3

2-oxo-propionic acid

Conditions
ConditionsYield
With Escherichia coli cystathionine β-lyase R58A mutant; pyridoxal 5'-phosphate; 2-amino-2-hydroxymethyl-1,3-propanediol at 25℃; pH=8.5; Kinetics; Reagent/catalyst; pH-value; aq. buffer;
MNLIINGENKSFEKEGLSVKELLVLESVKMPEMVSIQLNDEFLREPEYATTSLKEGDTINFLYFMGGG-X; X = S-bound-L-homocysteine

MNLIINGENKSFEKEGLSVKELLVLESVKMPEMVSIQLNDEFLREPEYATTSLKEGDTINFLYFMGGG-X; X = S-bound-L-homocysteine

A

L-homocysteine
6027-13-0

L-homocysteine

B

MNLIINGENKSFEKEGLSVKELLVLESVKMPEMVSIQLNDEFLREPEYATTSLKEGDTINFLYFMGGG

MNLIINGENKSFEKEGLSVKELLVLESVKMPEMVSIQLNDEFLREPEYATTSLKEGDTINFLYFMGGG

Conditions
ConditionsYield
With hcyD Enzymatic reaction;
O-acetyl-L-homoserine
7540-67-2

O-acetyl-L-homoserine

L-homocysteine
6027-13-0

L-homocysteine

Conditions
ConditionsYield
With sodium sulfide; O-acetyl-L-homoserine sulfhydrylase at 26℃; for 1h; pH=8; aq. phosphate buffer; Enzymatic reaction;
With O-acetylhomoserine sulfhydrylase; hydrogen sulfide Enzymatic reaction;
L-cystathionine
56-88-2

L-cystathionine

A

L-serin
56-45-1

L-serin

B

L-homocysteine
6027-13-0

L-homocysteine

Conditions
ConditionsYield
With 5,5'-dithiobis-(2-nitrobenzoic acid); yeast cystathionine β-synthase N84A mutant; water at 37℃; pH=8.6; Kinetics; Reagent/catalyst; Concentration; aq. buffer; Enzymatic reaction;
L-cystathionine
56-88-2

L-cystathionine

L-homocysteine
6027-13-0

L-homocysteine

Conditions
ConditionsYield
With 5,5'-dithiobis-(2-nitrobenzoic acid); cystathionine β-lyase In aq. phosphate buffer at 25℃; pH=8.5; Kinetics; Reagent/catalyst; Enzymatic reaction;
L-cystathionine
56-88-2

L-cystathionine

A

L-Cysteine
52-90-4

L-Cysteine

B

L-homocysteine
6027-13-0

L-homocysteine

C

ammonia
7664-41-7

ammonia

D

piruvate
57-60-3

piruvate

E

2-keto-butyrate
339-71-9

2-keto-butyrate

Conditions
ConditionsYield
With potassium phosphate; 5,5'-dithiobis-(2-nitrobenzoic acid); pyridoxal 5'-phosphate; cystathionine γ-lyase from Saccharomyces cerevisiae In aq. buffer pH=7.2; Kinetics; Reagent/catalyst; Enzymatic reaction;
L-homocysteine
6027-13-0

L-homocysteine

S-nitroso-L-homocysteine
139427-42-2

S-nitroso-L-homocysteine

Conditions
ConditionsYield
With hydrogenchloride; sodium nitrite at 20℃; for 0.25h;100%
With hydrogenchloride; sodium nitrite at 25℃; Product distribution; other biological reduced thiols, other temperature;92 % Chromat.
With hydrogenchloride; sodium nitrite at 25℃;92 % Chromat.
Stage #1: L-homocysteine With hydrogenchloride In water at 0 - 4℃; pH=1 - 2;
Stage #2: With sodium nitrite In water for 0.166667h; Darkness;
L-homocysteine
6027-13-0

L-homocysteine

5'-(chloromethyl)-5'-deoxyadenosine
477873-39-5

5'-(chloromethyl)-5'-deoxyadenosine

(S)-2-Amino-4-{2-[(2R,3S,4R,5R)-5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-ethylsulfanyl}-butyric acid

(S)-2-Amino-4-{2-[(2R,3S,4R,5R)-5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-ethylsulfanyl}-butyric acid

Conditions
ConditionsYield
With sodium hydroxide at 60℃; for 17h;100%
L-homocysteine
6027-13-0

L-homocysteine

S-[15N]nitroso-L-homocysteine

S-[15N]nitroso-L-homocysteine

Conditions
ConditionsYield
With hydrogenchloride; sodium (15)N-nitrite at 20℃; for 0.25h;100%
methanol
67-56-1

methanol

L-homocysteine
6027-13-0

L-homocysteine

L-Homocystine dimethyl ester dihydrochloride

L-Homocystine dimethyl ester dihydrochloride

Conditions
ConditionsYield
With thionyl chloride at 20℃; Cooling with ice;100%
With thionyl chloride Cooling with ice;10.6 g
L-homocysteine
6027-13-0

L-homocysteine

((2-(2-(fluoro-18F)ethoxy)ethyl)sulfonyl)ethane

((2-(2-(fluoro-18F)ethoxy)ethyl)sulfonyl)ethane

C10H20(18)FNO5S2

C10H20(18)FNO5S2

Conditions
ConditionsYield
at 25℃; for 0.5h; pH=8.5;98%
Conditions
ConditionsYield
With dihydrogen peroxide for 8h;95.7%
With air for 13h; Oxidation;40%
In water at 20℃; for 168000h; light irradiation;
With air In water at 40℃; for 24h;
With fluorone black In methanol; water at 20℃; for 0.0833333h; pH=7.3;
formaldehyd
50-00-0

formaldehyd

L-homocysteine
6027-13-0

L-homocysteine

L-3-Methyltetrahydro-1,3-thiazine
105013-85-2

L-3-Methyltetrahydro-1,3-thiazine

Conditions
ConditionsYield
With formic acid In water at 70℃; for 1.1h;84%
L-homocysteine
6027-13-0

L-homocysteine

2-(4-(benzo[d]thiazol-2-yl)-2-methoxyphenoxy)-N’-(2-chloroacetyl)acetohydrazide

2-(4-(benzo[d]thiazol-2-yl)-2-methoxyphenoxy)-N’-(2-chloroacetyl)acetohydrazide

2-(2-(2-(2-(4-(benzo[d]thiazol-2-yl)-2-methoxyphenoxy)acetyl)hydrazinyl)-2-oxoethylamino)-4-mercaptobutanoic acid

2-(2-(2-(2-(4-(benzo[d]thiazol-2-yl)-2-methoxyphenoxy)acetyl)hydrazinyl)-2-oxoethylamino)-4-mercaptobutanoic acid

Conditions
ConditionsYield
With triethylamine In dichloromethane at 20℃; for 27h; Cooling with ice;80%
L-homocysteine
6027-13-0

L-homocysteine

benzyl chloride
100-44-7

benzyl chloride

S-benzyl-L-homocysteine
7689-60-3

S-benzyl-L-homocysteine

Conditions
ConditionsYield
With 1,8-diazabicyclo[5.4.0]undec-7-ene In acetonitrile for 20h;78%
L-homocysteine
6027-13-0

L-homocysteine

[Pd(1R,2R-diaminocyclohexane)Cl2]

[Pd(1R,2R-diaminocyclohexane)Cl2]

silver perchlorate

silver perchlorate

[(1,2-trans-R,R-diaminocyclohexane)Pd(N,S-methionine)]ClO4

[(1,2-trans-R,R-diaminocyclohexane)Pd(N,S-methionine)]ClO4

Conditions
ConditionsYield
With sodium hydroxide In water byproducts: AgCl; Ag salt was added dropwise to soln. of Pd complex in H2O at 50-60°C; stirred for 2 h; filtered; soln. of ligand was added with stirring; NaOH was added to pH 6; stirred at 40-50°C for 6 h; cooled; recrystd. (hot H2O); elem. anal.;74%
[13C]methyl iodide
4227-95-6

[13C]methyl iodide

L-homocysteine
6027-13-0

L-homocysteine

[methyl-13C]-L-methionine
49705-26-2

[methyl-13C]-L-methionine

Conditions
ConditionsYield
With 1,8-diazabicyclo[5.4.0]undec-7-ene In acetonitrile for 23h;73%
triphenylmethyl alcohol
76-84-6

triphenylmethyl alcohol

L-homocysteine
6027-13-0

L-homocysteine

(2S)-2-amino-4-(tritylsulfanyl)butanoic acid
69955-57-3

(2S)-2-amino-4-(tritylsulfanyl)butanoic acid

Conditions
ConditionsYield
Stage #1: triphenylmethyl alcohol; L-homocysteine With trifluoroacetic acid In chloroform at 20℃; for 3h; Inert atmosphere; Cooling with ice;
Stage #2: With sodium hydroxide In water at 10℃; pH=13;
Stage #3: With citric acid In water pH=4;
70%
L-homocysteine
6027-13-0

L-homocysteine

sodium ethanesulfinate
20035-08-9

sodium ethanesulfinate

S-ethylsulfonyl-L-homocysteine

S-ethylsulfonyl-L-homocysteine

Conditions
ConditionsYield
Stage #1: L-homocysteine With hydrogenchloride; sodium nitrite In water at 0℃; for 0.5h;
Stage #2: sodium ethanesulfinate With hydrogenchloride In water at 0℃; Inert atmosphere;
66%
L-homocysteine
6027-13-0

L-homocysteine

5'-deoxy-5'-iodo-3-deazaadenosine
79782-13-1

5'-deoxy-5'-iodo-3-deazaadenosine

S-(3-deazaadenosyl)-L-homocysteine
53199-57-8

S-(3-deazaadenosyl)-L-homocysteine

Conditions
ConditionsYield
With ammonia; sodium65%
L-homocysteine
6027-13-0

L-homocysteine

4-<<4'-(N,N-dimethylamino)phenyl-1'>azo>benzaldehyde
39208-00-9

4-<<4'-(N,N-dimethylamino)phenyl-1'>azo>benzaldehyde

(S)-2-[4-(4-Dimethylamino-phenylazo)-phenyl]-[1,3]thiazinane-4-carboxylic acid

(S)-2-[4-(4-Dimethylamino-phenylazo)-phenyl]-[1,3]thiazinane-4-carboxylic acid

Conditions
ConditionsYield
In N,N-dimethyl-formamide62%
L-homocysteine
6027-13-0

L-homocysteine

cyanomethyl bromide
590-17-0

cyanomethyl bromide

(2S)-2-amino-4-[(cyanomethyl)sulfanyl]butanoic acid
1494537-63-1

(2S)-2-amino-4-[(cyanomethyl)sulfanyl]butanoic acid

Conditions
ConditionsYield
With potassium carbonate In acetone at 20℃;59%
With potassium carbonate In acetone at 20℃;59%
L-homocysteine
6027-13-0

L-homocysteine

5'-chloro-5'-deoxyadenosine-3'-d
99232-95-8

5'-chloro-5'-deoxyadenosine-3'-d

S-adenosyl-L-homocysteine-3'-d
99232-96-9

S-adenosyl-L-homocysteine-3'-d

Conditions
ConditionsYield
With sodium In ammonia52%
L-homocysteine
6027-13-0

L-homocysteine

N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide
82911-69-1

N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide

propyl tosylate
599-91-7

propyl tosylate

N-{[(9H-fluoren-9-yl)methoxy]carbonyl}-S-propyl-L-homocysteine

N-{[(9H-fluoren-9-yl)methoxy]carbonyl}-S-propyl-L-homocysteine

Conditions
ConditionsYield
Stage #1: L-homocysteine; propyl tosylate With sodium hydroxide In ethanol; water at 40℃; for 1.5h; Inert atmosphere;
Stage #2: N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide In tetrahydrofuran; water for 2h;
50.3%
(2S,3S,4R,5R)-2-(chloromethyl)-5-(2,6-diamino-9H-purin-9-yl)tetrahydrofuran-3,4-diol

(2S,3S,4R,5R)-2-(chloromethyl)-5-(2,6-diamino-9H-purin-9-yl)tetrahydrofuran-3,4-diol

L-homocysteine
6027-13-0

L-homocysteine

S-(2-aminoadenosyl)-L-homocysteine

S-(2-aminoadenosyl)-L-homocysteine

Conditions
ConditionsYield
With sodium hydroxide at 80℃; for 3h;47%
L-homocysteine
6027-13-0

L-homocysteine

GLUTATHIONE
70-18-8

GLUTATHIONE

γ-glutamylmethionine

γ-glutamylmethionine

Conditions
ConditionsYield
With equine kidney γ-glutamyl transpeptidase In aq. buffer at 4℃; for 72h; pH=9; Enzymatic reaction;47%
L-homocysteine
6027-13-0

L-homocysteine

(S)-2-amino-3-chloropropanoic acid hydrochloride
51887-88-8

(S)-2-amino-3-chloropropanoic acid hydrochloride

(2S,2'S)-2-amino-4-(2'-amino-2'-carboxyethylsulfanyl)butanoic acid
2867-15-4

(2S,2'S)-2-amino-4-(2'-amino-2'-carboxyethylsulfanyl)butanoic acid

Conditions
ConditionsYield
With sodium hydroxide at 20℃; for 24h;44.4%
L-homocysteine
6027-13-0

L-homocysteine

allyl bromide
106-95-6

allyl bromide

(2S)-2-amino-4-(prop-2-en-1-ylsulfanyl)butanoic acid
16146-23-9

(2S)-2-amino-4-(prop-2-en-1-ylsulfanyl)butanoic acid

Conditions
ConditionsYield
With potassium carbonate In acetone at 20℃;41%
methanol
67-56-1

methanol

L-homocysteine
6027-13-0

L-homocysteine

(4R,5aS,7aS,7bR)-5,5a,6,7,7a,7b-hexahydro-7b-hydroxy-4-methyl-indeno[1,7-bc]furan-2(4H)-one
133613-71-5

(4R,5aS,7aS,7bR)-5,5a,6,7,7a,7b-hexahydro-7b-hydroxy-4-methyl-indeno[1,7-bc]furan-2(4H)-one

3β-(N-acetyl-L-homocysteine methyl ester)-2αβ,3-dihydrogaliellalactone

3β-(N-acetyl-L-homocysteine methyl ester)-2αβ,3-dihydrogaliellalactone

Conditions
ConditionsYield
Stage #1: L-homocysteine; (4R,5aS,7aS,7bR)-5,5a,6,7,7a,7b-hexahydro-7b-hydroxy-4-methyl-indeno[1,7-bc]furan-2(4H)-one With triethylamine In methanol at 20℃;
Stage #2: In tetrahydrofuran at 20℃; for 20h;
Stage #3: methanol With thionyl chloride
40%

6027-13-0Relevant articles and documents

Functional consequences of homocysteinylation of the elastic fiber proteins fibrillin-1 and tropoelastin

Hubmacher, Dirk,Cirulis, Judith T.,Miao, Ming,Keeley, Fred W.,Reinhardt, Dieter P.

, p. 1188 - 1198 (2010)

Homocystinuria caused by cystathionine-β-synthase deficiency represents a severe form of homocysteinemias, which generally result in various degrees of elevated plasma homocysteine levels. Marfan syndrome is caused by mutations in fibrillin-1, which is one of the major constituents of connective tissue microfibrils. Despite the fundamentally different origins, both diseases share common clinical symptoms in the connective tissue such as long bone overgrowth, scoliosis, and ectopia lentis, whereas they differ in others. Fibrillin-1 contains ~13% cysteine residues and can be modified by homocysteine. We report here that homocysteinylation affects functional properties of fibrillin-1 and tropoelastin. We used recombinant fragments spanning the entire fibrillin-1 molecule to demonstrate that homocysteinylation, but not cysteinylation leads to abnormal self-interaction, which was attributed to a reduced amount of multimerization of the fibrillin-1 C terminus. The deposition of the fibrillin-1 network by human dermal fibroblasts was greatly reduced by homocysteine, but not by cysteine. Furthermore, homocysteinylation, but not cysteinylation of elastin-like polypeptides resulted in modified coacervation properties. In summary, the results provide new insights into pathogenetic mechanisms potentially involved in cystathionine-β-synthase-deficient homocystinuria.

Identification of O-acetylhomoserine sulfhydrylase, a putative enzyme responsible for methionine biosynthesis in Clostridioides difficile: Gene cloning and biochemical characterizations

Kulikova, Vitalia V.,Revtovich, Svetlana V.,Bazhulina, Natalia P.,Anufrieva, Natalya V.,Kotlov, Mikhail I.,Koval, Vasiliy S.,Morozova, Elena A.,Hayashi, Hideyuki,Belyi, Yury F.,Demidkina, Tatyana V.

, p. 1815 - 1823 (2019)

O-acetylhomoserine sulfhydrylase (OAHS) is a pyridoxal 5′-phosphate-dependent enzyme involved in microbial methionine biosynthesis. In this study, we report gene cloning, protein purification, and some biochemical characteristics of OAHS from Clostridioides difficile. The enzyme is a tetramer with molecular weight of 185 kDa. It possesses a high activity in the reaction of L-homocysteine synthesis, comparable to reported activities of OAHSes from other sources. OAHS activity is inhibited by metabolic end product L-methionine. L-Propargylglycine was found to be a suicide inhibitor of the enzyme. Substrate analogue Nγ-acetyl-L-2,4-diaminobutyric acid is a competitive inhibitor of OAHS with Ki = 0.04 mM. Analysis of C. difficile genome allows to suggest that the bacterium uses the way of direct sulfhydrylation for the synthesis of L-methionine. The data obtained may provide the basis for further study of the role of OAHS in the pathogenic bacterium and the development of potential inhibitors.

COMPOSITONS AND METHODS FOR TREATING BRAIN INJURY

-

Page/Page column 42, (2020/02/06)

A method for treating a hyperhomocysteinemic subject having cerebral ischemic stroke generally includes administering to the hyperhomocysteinemic subject, following cerebral stroke, a composition that includes an inhibitor or an antagonist of a GluN2A-containing N-methyl-D-aspartate receptor (NMDAR) in an amount effective to ameliorate at least one symptom or clinical sign of cerebral stroke.

Poly(S-ethylsulfonyl- l -homocysteine): An α-Helical Polypeptide for Chemoselective Disulfide Formation

Muhl, Christian,Sch?fer, Olga,Bauer, Tobias,R?der, Hans-Joachim,Barz, Matthias

, p. 8188 - 8196 (2018/10/31)

Homocysteine and cysteine are the only natural occurring amino acids that are capable of disulfide bond formations in peptides and proteins. The chemoselective formation of asymmetric disulfide bonds, however, is chemically challenging and requires an activating group combining stability against hard nucleophiles, e.g., amines, with reactivity toward thiols and soft nucleophiles. In light of these considerations, we introduced the S-alkylsulfonyl cysteines in our previous work. Here, we present the synthesis and ring-opening polymerization of S-ethylsulfonyl-l-homocysteine N-carboxyanhydrides. We demonstrate that the polymerization leads to narrowly distributed polypeptides (D= 1.1-1.3) with no detectable side reactions in a chain length regime from 11 to 165. In contrast to the already reported cysteine derivatives, poly(S-ethylsulfonyl-l-homocysteine)s do not form β-sheets, which reduce solubility and limit the degree of polymerization of poly(S-ethylsulfonyl-l-cysteine)s to 50. Instead, these polymers form α-helices as confirmed by circular dicroism (CD) experiments and infrared spectroscopy (FT-IR). In comparison to the cysteine derivatives, the α-helix formation leads to slightly faster polymerization kinetics (rate constants from 1.44 × 10-5 to 5.29 × 10-5 s-1). In addition, the ability for the chemoselective formation of asymmetric disulfides is preserved as monitored via 1H NMR experiments. Consequently, this new polypeptide overcomes the chain length limitations of poly(S-ethylsulfonyl-l-cysteine)s and thus provides convenient access to reactive poly(S-ethylsulfonyl-l-homocysteine)s for chemoselective disulfide formation.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 6027-13-0